DGAP-News

MOLOGEN AG publishes nine month report for 2014: launch of pivotal study for the cancer immunotherapy MGN1703 - Seite 2

completed clinical phase I/II trial (ASET) on MGN1601 was presented at the
international ESMO Congress (European Society for Medical Oncology).

Research expenses have increased due to the ongoing studies.
The interim report of MOLOGEN as of September 30, 2014 accounts for the
extensive work on the study program and at the same time reflects the sound
financial situation. As expected, expenses for research and development
(R&D) increased over the first nine months of 2014, to 10.5 million Euros.
In the previous year the amount of 4.5 million Euros had been invested.
This rise reflects the enhanced efforts for the preparation and initiation
of clinical trials, with a view to making further progress for the product
candidates. The higher R&D expenses have resulted in a corresponding loss
of 13.3 million Euros for the reporting period (same period of the previous
year: -6.8 million Euros).

MOLOGEN continues to have stable finances as a result of a capital increase
that was implemented in February. As at the end of third quarter of 2014,
MOLOGEN AG had cash and cash equivalents of around 18 million Euros.

The nine month report published today confirms our forecast for the year as
a whole, as stated in previous quarterly reports. The Executive Board is
expecting the net loss for the year to be considerably above the comparable
figure for the previous year on account of the increased R&D investments.
The complete MOLOGEN report as of September 30, 2014 can be found online
at: http://www.mologen.com/de/investoren-presse.html.


MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and
clinical development of cancer immune therapies and DNA vaccines against
infectious diseases.

The cancer immune therapy MGN1703 is the company's lead product and
best-in-class TLR-9 agonist. It is currently developed for first-line
maintenance treatment of colorectal cancer (pivotal randomized trial) and
lung cancer (randomized controlled trial). A second clinical-stage product
is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A
phase I/II clinical study has already been completed successfully.

With unique, patented technologies and innovative products, MOLOGEN is
pioneering immune therapies.

MOLOGEN AG is a publicly listed company, headquartered in Berlin. The
shares (ISIN DE0006637200) are listed in the Prime Standard of the German
Stock Exchange.

www.mologen.com

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.